Michael P. Brown - Concepedia

Author

Michael P. Brown

Also Known As

BROWN, MH, Brown, Michael P., M Brown, M C Brown, M P Brown, M. Brown, M. C. Brown, M. P. BROWN, M. P. Brown, M. P. S. Brown

425

Publications

18.6K

Citations

H-Index

235

Concepts

All Affiliations

Royal Adelaide Hospital The University of Adelaide University of South Australia Centre for Cancer Biology South Australia Pathology

About

Michael P. Brown is an author at Royal Adelaide Hospital specializing in medicine, engineering, and chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	64	9.6K
2	Engineering	25	49	4K
3	Health Sciences	14	14	974
4	Language Studies	2	2	78
5	Humanities	1	1	26

Michael P. Brown

195

Publications

15.9K

Citations

H-Index

Page 1

	Year	Citations
Knowledge-based analysis of microarray gene expression data by using support vector machines Michael P. Brown, William Noble Grundy, David Lin, Proceedings of the National Academy of Sciences EngineeringMachine LearningFeature SelectionGene RecognitionGene Expression Profiling	2000	2.3K
Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses Stephan Teglund, Catriona McKay, Erin G. Schuetz, Cell InflammationCytokineSignal TransductionAutoimmune DiseaseCytokine Responses	1998	1.3K
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Georgina V. Long, Victoria Atkinson, Serigne Lo, The Lancet Oncology Neuro-oncologyMelanoma Brain MetastasesMedicineMelanomaPathology	2018	975
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, The Lancet Neuro-oncologyUntreated Brain MetastasesMedicineMelanomaPharmacotherapy	2012	928
Stochastic context-free grammers for tRNA modeling Yasubumi Sakakibara, Michael P. Brown, Richard Hughey, Nucleic Acids Research	1994	389
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade Tessa Gargett, Wenbo Yu, Gianpietro Dotti, Molecular Therapy	2016	349
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study James Larkin, Michele Del Vecchio, Paolo A. Ascierto, The Lancet Oncology MedicineMelanomaSafety StudyPathologyMetastatic Melanoma	2014	289
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown, Journal of Clinical Oncology Phase I/ii StudyMut Braf MelanomaImmunotherapeuticsCancer BiologyTumor Biology	2010	274
Total percutaneous access for endovascular aortic aneurysm repair (“Preclose” technique) W. Anthony Lee, Michael P. Brown, Peter R. Nelson, Journal of Vascular Surgery Endovascular TechniqueArterial ReconstructionsVascular SurgeryTotal Percutaneous AccessSurgery	2007	252

Page 1